On the public citation graph

Strategic Disclosure in R&D Races: Theory and Evidence

https://doi.org/10.2139/ssrn.5895603
0 signed · 68 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2013.281053openalex-snapshot
World Medical Association Declaration of Helsinki
inferredcites →https://doi.org/10.1007/s11142-014-9299-2openalex-snapshot
Discretionary disclosure, spillovers, and competition
inferredcites →https://doi.org/10.1007/s11142-018-9463-1openalex-snapshot
Competition and voluntary disclosure: evidence from deregulation in the banking industry
inferredcites →https://doi.org/10.1007/s11142-019-09520-0openalex-snapshot
Discretionary disclosure and manager horizon: evidence from patenting
inferredcites →https://doi.org/10.1016/0165-1765(94)00522-4openalex-snapshot
Strategic R&D success announcements
inferredcites →https://doi.org/10.1016/0165-4101(90)90048-9openalex-snapshot
Financial disclosure policy in an entry game
inferredcites →https://doi.org/10.1016/j.jacceco.2010.10.003openalex-snapshot
The financial reporting environment: Review of the recent literature
inferredcites →https://doi.org/10.1016/j.jacceco.2012.01.003openalex-snapshot
Incentives for innovation and centralized versus delegated capital budgeting
inferredcites →https://doi.org/10.1016/j.jacceco.2014.08.008openalex-snapshot
Linking industry concentration to proprietary costs and disclosure: Challenges and opportunities
inferredcites →https://doi.org/10.1016/j.jacceco.2017.11.001openalex-snapshot
Accounting Standards, Regulatory Enforcement, and Innovation
inferredcites →https://doi.org/10.1016/j.jacceco.2018.02.001openalex-snapshot
Transparency and firm innovation
inferredcites →https://doi.org/10.1016/j.jacceco.2018.04.002openalex-snapshot
The Effects of Proprietary Information on Corporate Disclosure and Transparency: Evidence from Trade Secrets
inferredcites →https://doi.org/10.1016/j.jacceco.2020.101319openalex-snapshot
Effects of accounting conservatism on investment efficiency and innovation
inferredcites →https://doi.org/10.1016/j.jfineco.2010.02.009openalex-snapshot
The real effects of financial constraints: Evidence from a financial crisis
inferredcites →https://doi.org/10.1016/j.jhealeco.2016.01.012openalex-snapshot
Innovation in the pharmaceutical industry: New estimates of R&D costs
inferredcites →https://doi.org/10.1016/j.jmoneco.2020.11.002openalex-snapshot
A unified measure of Fed monetary policy shocks
inferredcites →https://doi.org/10.1016/j.jpubeco.2012.10.003openalex-snapshot
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
inferredcites →https://doi.org/10.1016/s0140-6736(20)30977-6openalex-snapshot
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019
inferredcites →https://doi.org/10.1016/s0165-4101(01)00024-6openalex-snapshot
An evaluation of “essays on disclosure” and the disclosure literature in accounting
inferredcites →https://doi.org/10.1038/nbt.2786openalex-snapshot
Clinical development success rates for investigational drugs
inferredcites →https://doi.org/10.1038/nrd4164openalex-snapshot
Does size matter in R&D productivity? If not, what does?
inferredcites →https://doi.org/10.1038/nrd4697openalex-snapshot
Forecasting market share in the US pharmaceutical market
inferredcites →https://doi.org/10.1056/nejmsr1601330openalex-snapshot
Update on Trial Registration 11 Years after the ICMJE Policy Was Established
inferredcites →https://doi.org/10.1086/466995openalex-snapshot
The Informational Role of Warranties and Private Disclosure about Product Quality
inferredcites →https://doi.org/10.1086/712506openalex-snapshot
Killer Acquisitions
inferredcites →https://doi.org/10.1086/723636openalex-snapshot
Patent Publication and Innovation
inferredcites →https://doi.org/10.1093/biostatistics/kxx069openalex-snapshot
Estimation of clinical trial success rates and related parameters
inferredcites →https://doi.org/10.1093/restud/rdy034openalex-snapshot
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
inferredcites →https://doi.org/10.1093/rfs/14.2.529openalex-snapshot
Financial Constraints and Stock Returns
inferredcites →https://doi.org/10.1093/rfs/hhr043openalex-snapshot
Financial Constraints, R&D Investment, and Stock Returns
inferredcites →https://doi.org/10.1093/rfs/hhv052openalex-snapshot
Do Measures of Financial Constraints Measure Financial Constraints?
inferredcites →https://doi.org/10.1093/rfs/hhz140openalex-snapshot
Financial Constraints, Monetary Policy Shocks, and the Cross-Section of Equity Returns
inferredcites →https://doi.org/10.1111/1468-0009.12244openalex-snapshot
Volunteering for Clinical Research Studies and Public Health
inferredcites →https://doi.org/10.1111/1475-679x.12043openalex-snapshot
How Frequent Financial Reporting Can Cause Managerial Short‐Termism: An Analysis of the Costs and Benefits of Increasing Reporting Frequency
inferredcites →https://doi.org/10.1111/1475-679x.12115openalex-snapshot
The Economics of Disclosure and Financial Reporting Regulation: Evidence and Suggestions for Future Research
inferredcites →https://doi.org/10.1111/1475-679x.12398openalex-snapshot
The Innovation and Reporting Consequences of Financial Regulation for Young Life‐Cycle Firms
inferredcites →https://doi.org/10.1111/1475-679x.12509openalex-snapshot
Corporate R&D Investments Following Competitors’ Voluntary Disclosures: Evidence from the Drug Development Process
inferredcites →https://doi.org/10.1111/1475-679x.12546openalex-snapshot
Innovation and Financial Disclosure
inferredcites →https://doi.org/10.1111/1475-679x.12580openalex-snapshot
Disclosure, Patenting, and Trade Secrecy
inferredcites →https://doi.org/10.1111/1911-3846.12758openalex-snapshot
Regulatory Approval and Biotechnology Product Disclosures*†
inferredcites →https://doi.org/10.1111/1911-3846.12848openalex-snapshot
Information Transparency and Investment in Follow‐on Innovation*
inferredcites →https://doi.org/10.1111/1911-3846.12870openalex-snapshot
Technological peer pressure and skill specificity of job postings
inferredcites →https://doi.org/10.1111/j.1475-679x.2004.00140.xopenalex-snapshot
Competitive Costs of Disclosure by Biotech IPOs
inferredcites →https://doi.org/10.1111/j.1540-6261.2004.00679.xopenalex-snapshot
The Cash Flow Sensitivity of Cash
inferredcites →https://doi.org/10.1111/j.1540-6261.2011.01688.xopenalex-snapshot
Motivating Innovation
inferredcites →https://doi.org/10.1146/annurev-financial-031721-081537openalex-snapshot
Financing Biomedical Innovation
inferredcites →https://doi.org/10.1177/1740774515625964openalex-snapshot
Key cost drivers of pharmaceutical clinical trials in the United States
inferredcites →https://doi.org/10.1257/aer.20131176openalex-snapshot
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
inferredcites →https://doi.org/10.1257/aer.20151398openalex-snapshot
How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome
inferredcites →https://doi.org/10.1257/jel.20161327openalex-snapshot
Economics of the Pharmaceutical Industry
inferredcites →https://doi.org/10.1287/mnsc.2020.3775openalex-snapshot
Trials and Terminations: Learning from Competitors’ R&D Failures
inferredcites →https://doi.org/10.1287/mnsc.2023.4721openalex-snapshot
Asymmetric Information and R&D Disclosure: Evidence from Scientific Publications
inferredcites →https://doi.org/10.1287/mnsc.2023.4780openalex-snapshot
Breaking it Down: Economic Consequences of Disaggregated Cost Disclosures
inferredcites →https://doi.org/10.1506/9n45-f0jx-axvw-lbwjopenalex-snapshot
Voluntary Disclosure and Equity Offerings: Reducing Information Asymmetry or Hyping the Stock?*
inferredcites →https://doi.org/10.2307/2118465openalex-snapshot
Monetary Policy, Business Cycles, and the Behavior of Small Manufacturing Firms
inferredcites →https://doi.org/10.2307/2600992openalex-snapshot
Dynamic R&D Competition under "Hazard Rate" Uncertainty
inferredcites →https://doi.org/10.2307/3003562openalex-snapshot
Good News and Bad News: Representation Theorems and Applications
inferredcites →https://doi.org/10.2308/accr-10034openalex-snapshot
What Makes Conference Calls Useful? The Information Content of Managers' Presentations and Analysts' Discussion Sessions
inferredcites →https://doi.org/10.2308/accr-50649openalex-snapshot
Narrative Disclosure and Earnings Performance: Evidence from R&D Disclosures
inferredcites →https://doi.org/10.2308/accr-51418openalex-snapshot
Come on Over: Analyst/Investor Days as a Disclosure Medium
inferredcites →https://doi.org/10.2308/accr-51778openalex-snapshot
Analysts' Influence on Managers' Guidance
inferredcites →https://doi.org/10.2308/accr-52056openalex-snapshot
Technological Peer Pressure and Product Disclosure
inferredcites →https://doi.org/10.2308/jfr-2018-0026openalex-snapshot
On Market Concentration and Disclosure
inferredcites →https://doi.org/10.2308/jfr-2023-021openalex-snapshot
Fixing the Proprietary Cost Assumption in Discretionary Disclosure Models
inferredcites →https://doi.org/10.2308/tar-2019-0137openalex-snapshot
Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results
inferredcites →https://doi.org/10.2308/tar-2019-1050openalex-snapshot
Deterrent Disclosure
inferredcites →https://doi.org/10.2308/tar-2023-0310openalex-snapshot
Unintended Real Effects of EDGAR: Evidence from Corporate Innovation
inferredcites →https://doi.org/10.2310/jim.0b013e3181afdb26openalex-snapshot
Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.